· Renpio 15 Tablet is taken orally.

‍

Renpio 15 Tablet contains pioglitazone (15 mg), which works through the following mechanisms:

· Agonist of PPAR-γ: Pioglitazone activates peroxisome proliferator-activated receptor-gamma (PPAR-γ), involved in regulating genes related to glucose and lipid metabolism.

· Increases Insulin Sensitivity: By activating PPAR-γ receptors, pioglitazone enhances the sensitivity of insulin-dependent tissues like adipose tissue, skeletal muscles, and the liver, resulting in more efficient glucose utilisation and reduced hepatic glucose production.

· Blood Lipids Management: Pioglitazone manages blood lipids, reducing triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol, often referred to as 'good' cholesterol.

‍

Renpio 15 Tablet interacts with:

· CYP2C8 Inhibitors: May affect the metabolism of this tablet.

· CYP2C8 Inducers: May reduce the effectiveness of pioglitazone.

· Insulin or Insulin Secretagogues: Increases the risk of hypoglycaemia.

· Oral Contraceptives: May decrease the effectiveness of oral contraceptives.

Drug-Disease Interactions

· Type 1 Diabetes and Diabetic Ketoacidosis: Ineffective as it does not address the insulin deficiency.

· Heart Failure (NYHA Class III or IV): May exacerbate heart failure symptoms.

‍

Daily Dosage

· This tablet is taken as prescribed by your doctor, tailored to your specific condition and response.

Missed Dose

· If you miss a dose, take it as soon as you remember. If it is close to the time of your next dose, skip the missed dose. Do not double the dose.

Overdose

· Symptoms of overdose may include headache, sinusitis, or muscle pain. Seek medical attention if symptoms persist.

‍

· Store this tablet at room temperature.

· Protect from light and moisture.

· Keep out of reach of children.

· Use before the expiration date on the packaging.

‍

· Adopt a balanced diet rich in fibre and low in simple sugars.

· Engage in regular physical activity to support glucose control.

‍